Insight Molecular Diagnostics Inc. (IMDX)Healthcare | Diagnostics & Research | Nashville, United States | NasdaqCM
3.01 USD
-0.05
(-1.634%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:54 a.m. EDT
The long-term investment case is severely compromised by a decade-long structural decline. Despite a recent year-over-year price recovery, the asset has lost 96.64% of its value over the last nine years, with six of those years seeing negative returns. This is not a temporary setback; it is a business in freefall with negative earnings, negative free cash flow, and a negative book value. The market has correctly priced this as a failing enterprise, rendering any 'value' narrative moot. On the short end, the stock is a speculative vehicle driven entirely by options flow. Traders are buying deep out-of-the-money calls hoping for a miracle turnaround while hedging with deep puts, creating a volatile trading environment detached from reality. With no dividend to provide income and a balance sheet that cannot support operations, this is a high-risk gamble suitable only for capital destined to be lost. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.044087 |
| MSTL | 0.125733 |
| AutoETS | 0.129358 |
| AutoARIMA | 0.129660 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.16 |
| Ljung-Box p | 0.018 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.049 |
| Market Cap | 98,500,096 |
| Forward P/E | -3.76 |
| Beta | 1.81 |
| Previous Name | OncoCyte Corporation |
| Website | https://www.imdxinc.com |
As of Oct. 10, 2026, 2:54 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional move. Call volume is heavily skewed toward out-of-the-money strikes (7.0 and 6.0) with massive open interest, suggesting a bet on a sharp rally. Conversely, put open interest is concentrated deep in-the-money (2.0 strike), indicating a hedge against a crash to lower levels. The implied volatility gap between calls and puts suggests a 'long gamma' environment where the market expects a binary event, but the lack of directional bias in volume implies uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.48896432 |
| Address1 | 2 International Plaza Dr. |
| Address2 | Suite 510 |
| All Time High | 204.8 |
| All Time Low | 1.922 |
| Ask | 3.8 |
| Ask Size | 2 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 270,510 |
| Average Daily Volume3 Month | 230,050 |
| Average Volume | 230,050 |
| Average Volume10Days | 270,510 |
| Beta | 1.805 |
| Bid | 2.3 |
| Bid Size | 2 |
| Book Value | -0.653 |
| City | Nashville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.01 |
| Current Ratio | 1.997 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.14 |
| Day Low | 2.89 |
| Display Name | Insight Molecular Diagnostics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,395,600 |
| Earnings Call Timestamp Start | 1,786,395,600 |
| Earnings Timestamp | 1,786,392,000 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -34,543,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.413 |
| Enterprise To Revenue | 49.922 |
| Enterprise Value | 83,369,096 |
| Eps Current Year | -0.925 |
| Eps Forward | -0.8 |
| Eps Trailing Twelve Months | -1.52 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.8984 |
| Fifty Day Average Change | -0.8884001 |
| Fifty Day Average Change Percent | -0.22788838 |
| Fifty Two Week Change Percent | -48.89643 |
| Fifty Two Week High | 8.51 |
| Fifty Two Week High Change | -5.5 |
| Fifty Two Week High Change Percent | -0.64629847 |
| Fifty Two Week Low | 2.42 |
| Fifty Two Week Low Change | 0.5899999 |
| Fifty Two Week Low Change Percent | 0.24380161 |
| Fifty Two Week Range | 2.42 - 8.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,451,485,800,000 |
| Float Shares | 9,977,961 |
| Forward Eps | -0.8 |
| Forward P E | -3.7625 |
| Free Cashflow | -18,789,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 55 |
| Fullday Change | -0.049999952 |
| Fullday Change Percent | -1.6339854 |
| Fullday Price | 3.01 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.48743 |
| Gross Profits | 814,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.20999001 |
| Held Percent Institutions | 0.57537 |
| Implied Shares Outstanding | 32,724,284 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,690,243,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee. |
| Long Name | Insight Molecular Diagnostics Inc. |
| Market | us_market |
| Market Cap | 98,500,096 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_78474527 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-17 |
| Net Income To Common | -49,359,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 128,115,571 |
| Number Of Analyst Opinions | 4 |
| Open | 3.07 |
| Operating Cashflow | -27,078,000 |
| Operating Margins | -38.15063 |
| Phone | 949 409 7600 |
| Prev Name | OncoCyte Corporation |
| Previous Close | 3.06 |
| Price Eps Current Year | -3.254054 |
| Price Hint | 4 |
| Price To Book | -4.6094947 |
| Price To Sales Trailing12 Months | 58.982094 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.745 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -1.63399 |
| Regular Market Day High | 3.14 |
| Regular Market Day Low | 2.89 |
| Regular Market Day Range | 2.89 - 3.14 |
| Regular Market Open | 3.07 |
| Regular Market Previous Close | 3.06 |
| Regular Market Price | 3.01 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 181,499 |
| Return On Assets | -0.5782 |
| Revenue Growth | -0.539 |
| Revenue Per Share | 0.049 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 32,724,284 |
| Shares Percent Shares Out | 0.0297 |
| Shares Short | 973,029 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 930,741 |
| Short Name | Insight Molecular Diagnostics I |
| Short Percent Of Float | 0.0598 |
| Short Ratio | 3.57 |
| Source Interval | 15 |
| State | TN |
| Symbol | IMDX |
| Target High Price | 12.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 8.25 |
| Target Median Price | 8.5 |
| Total Cash | 17,756,000 |
| Total Cash Per Share | 0.543 |
| Total Debt | 2,625,000 |
| Total Revenue | 1,670,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.52 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.950075 |
| Two Hundred Day Average Change | -1.9400752 |
| Two Hundred Day Average Change Percent | -0.39192843 |
| Type Disp | Equity |
| Volume | 181,499 |
| Website | https://www.imdxinc.com |
| Zip | 37,217 |